Promoter methylation status of <i>RASSF1A</i> and <i>RASSF2A</i> tumor suppressor genes in endometrial endometrioid carcinomas

Atmaca H. N., GÜN S., Önal M., Tural Ş.

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, cilt.43, sa.11, ss.1369-1381, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 43 Sayı: 11
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1080/15257770.2024.2356744
  • Dergi Adı: NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Chemical Abstracts Core, Chimica, MEDLINE
  • Sayfa Sayıları: ss.1369-1381
  • Anahtar Kelimeler: endometrioid carcinoma, epigenetic, promoter hypermethylation, RASSF1A, RASSF2A, tumor supressor genes
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

We aimed to investigate the promoter methylation status of RASSF1A and RASSF2A tumor suppressor genes in endometrial endometrioid carcinomas with p53 wild type and mismatch repair proficient. Genomic DNAs were isolated from 50 specimens (15 formalin-fixed paraffin embedded tumor tissues, 15 paired blood samples and 20 normal endometrial tissues). Bisulfide modification and methylation-specific polymerase chain reaction were performed. As a result of the study, while no significance was found for RASSF1A gene (p = 0.08), a statistically significance was found for RASSF2A gene (p < 0.001), RASSF2A gene methylation status was also found higher in high grade tumors, advanced age (>= 50) and nonsmokers groups. Our results indicate that RASSF2A gene may play a role in the carcinogenesis of endometrioid and it could be potential biomarker for early detection for endometrioid carcinoma. Further and larger investigations are needed to confirm our results.